During the corresponding time, Tracon Pharmaceuticals Inc saw a revenue deteriorated by -99.39 % year on year, sequentially revenue fell by -45 %. While revenue at the Tracon Pharmaceuticals Inc 's corporate clients
Tracon Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company is responsible for commercializing YH001 in North America for the Initial and Substitute Indications and will market and distribute YH001 outside North America for all indications other than the Initial and Substitute Indications. The company owes Eucure escalating royalties on net sales of YH001 in North America and may owe a milestone payment if sales exceed a specified threshold. Eucure will manufacture and supply YH001 or arrange for third-party manufacturing. The collaboration agreement restricts both parties from developing or commercializing a monospecific inhibitor to CTLA-4 during its term. The agreement remains in effect until development ceases or royalty obligations expire, with provisions for termination and licensing rights upon termination.
In a recent announcement, TRACON Pharmaceuticals revealed the termination of its ENVASARC trial due to unsatisfactory results. This decision has prompted the company to explore strategic alternatives while harnessing its in-house product development platform. With the response rate falling short of the primary endpoint, TRACON Pharmaceuticals now faces a critical juncture in its drug discovery journey.1. The ENVASARC Trial:The ENVASARC trial, a pivotal study conducted by TRACON Pharmaceuticals, aimed to evaluate the efficacy of their investigational drug in treating a specific type of cancer. The trial enrolled 82 patients, with a primary endpoint set at an response rate of 11%. Unfortunately, the recently...
Promising New Data on TRC102 in Recurrent Glioblastoma: Enhancing Temodar Efficacy TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) has announced encouraging findings published in the peer-reviewed journal Clinical Cancer Research showcasing the efficacy of TRC102 in Phase 2 clinical trials involving recurrent glioblastoma patients. This study highlights the synergy between TRC102, a DNA damage repair inhibitor, and Temodar (temozolomide), an alkylating agent, in patients whose disease had recurred post primary treatment, signifying a potential breakthrough for those battling this aggressive brain cancer.Glioblastoma is notorious for its resistance to conventional therapies, underscoring the dire need for more ef...
Tracon Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company is responsible for commercializing YH001 in North America for the Initial and Substitute Indications and will market and distribute YH001 outside North America for all indications other than the Initial and Substitute Indications. The company owes Eucure escalating royalties on net sales of YH001 in North America and may owe a milestone payment if sales exceed a specified threshold. Eucure will manufacture and supply YH001 or arrange for third-party manufacturing. The collaboration agreement restricts both parties from developing or commercializing a monospecific inhibitor to CTLA-4 during its term. The agreement remains in effect until development ceases or royalty obligations expire, with provisions for termination and licensing rights upon termination.
Sources:
Tracon Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tracon Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Tracon Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
